AIMEE CHARLES: Open Payments
NPI 1841936952 · ORANGE PARK, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,377 in 127 payments from 19 companies in 2025. Trend: 2023 $2,582 · 2024 $3,364 · 2025 $2,377
Food & beverage: $2,377
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $438 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $305 |
| Alkermes, Inc. | 11 | $282 |
| Otsuka America Pharmaceutical, Inc. | 14 | $235 |
| Vanda Pharmaceuticals Inc. | 15 | $174 |
| Supernus Pharmaceuticals, Inc. | 14 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| Axsome Therapeutics, Inc. | 7 | $138 |
| Collegium Pharmaceutical, Inc. | 5 | $98 |
| Janssen Pharmaceuticals, Inc | 3 | $81 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Qelbree, TRINTELLIX, ARISTADA, FANAPT, LYBALVI.
Industry payments across FL — which companies pay providers there.
